𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Lack of effect of a booster dose of influenza vaccine in hemodialysis patients

✍ Scribed by Elisabetta Tanzi; Antonella Amendola; Elena Pariani; Alessandra Zappa; Daniela Colzani; Franco Logias; Angelo Perego; Alessandro R. Zanetti


Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
84 KB
Volume
79
Category
Article
ISSN
0146-6615

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

To assess whether the administration of a booster dose of influenza vaccine may enhance immune response in hemodialysis patients, 58 subjects were given two doses of the 2003/2004 season influenza vaccine, 1 month apart. “European Agency for the Evaluation of Medicinal Products” (EMEA) criteria were fully met in terms of percentage of response and of mean‐fold increase of hemagglutination inhibiting (HI) antibody titer, but not in terms of seroprotection rates (HI antibody titers ≥1:40). The second vaccine administration did not result in additional increase in seroprotection rate or in geometric mean titers. Protective immune response against the epidemic A/H3N2 Fujian‐like strain, antigenically distant from that included in the vaccine (A/Panama/2007/99) was observed in 94.7% of vaccinees protected against the A/H3N2 vaccine strain 1 month after immunization. No adverse reactions were reported during follow‐up. The study findings suggest that immune response to influenza vaccination may be suboptimal in hemodialysis patients and that the administration of an additional second dose of vaccine does not improve the humoral response. J. Med. Virol. 79: 1176–1179, 2007. © 2007 Wiley‐Liss, Inc.


📜 SIMILAR VOLUMES


Cost-effectiveness of influenza vaccinat
✍ Elenir B. C. Avritscher; Catherine D. Cooksley; Jane M. Geraci; Benjamin N. Beke 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 219 KB

## Abstract ## BACKGROUND. Despite recommendations to immunize all patients at an increased risk of influenza complications, the vaccine utilization among high‐risk nonelderly adults remains low and its cost‐effectiveness is unclear. In the current study, the authors analyzed the cost‐effectivenes

Lack of cross-immune reactivity against
✍ Julian W. Tang; Karry L.K. Ngai; Paul K.S. Chan 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 76 KB

## Abstract In a small pilot study, sera from 10 healthy human volunteers were taken pre‐vaccine, then 1, 3, and 6 months post‐seasonal influenza immunization (using the 2005/2006 Northern hemisphere vaccine: A/New Caledonia/20/99(H1N1)‐like, A/California/7/2004(H3N2)‐like, and B/Shanghai/361/2002‐

Immunogenicity of a single dose of triva
✍ Dr. Manfred S. Green; Colin Block; Lotte Rannon 📂 Article 📅 1986 🏛 John Wiley and Sons 🌐 English ⚖ 393 KB

During 1982, a new A(H3N2) influenza ViNS subtype, A/Philippines/2/82, was identified, and this strain was combined with previous A(HlN1) and B influenza virus strains in the trivalent inactivated vaccine recommended for the 1983-1984 influenza season. Prior to the widescale use of this vaccine in I